Literature DB >> 34648087

Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial.

Fabiola Carrara1, Piero Ruggenenti2,3, Annalisa Perna1, Ilian Petrov Iliev1, Flavio Gaspari1, Silvia Ferrari1, Nadia Stucchi1, Antonio Bossi4, Roberto Trevisan5, Giuseppe Remuzzi1,6, Aneliya Parvanova1.   

Abstract

AIMS: Investigating whether and to what extent changes in glomerular hemodynamic parameters, beyond glomerular hyperfiltration, could predict glomerular filtration rate (GFR) decline in hypertensive, non-proteinuric type 2 diabetic patients.
MATERIALS AND METHODS: We estimated baseline afferent (Ra) and efferent (Re) arteriolar resistances and glomerular hydrostatic pressure in 60 consecutive patients from DEMAND study, using the Gomez' equations. Baseline renal plasma flow was measured by para-aminohippurate plasma clearance, and GFR was measured by iohexol plasma clearance at baseline and every 6 months for a median of 4.0 years [IQR 3.5-4.0 years]. Patients with a GFR decline > or ≤ 3 mL/min/1.73 m2/year were categorized as "Progressors" and "Non-progressors," respectively. Predictors of GFR decline were studied by univariable and multivariable logistic regression analysis.
RESULTS: •The GFR declined by a median [IQR] of 4.06 [5.46-2.00] mL/min/1.73 m2/year in the study group as a whole and by 5.35 [6.60-4.48] mL/min/1.73 m2/year and 1.71 [2.14-1.33] mL/min/1.73 m2/year in Progressors and Non-progressors, considered separately. Progressors had a higher baseline Ra (3487.3 ± 1349.3 dyne•sec•cm-5 vs. 2877.0 ± 668.9 dyne•sec•cm-5, p < 0.05) and higher Ra/Re ratio (1.4 ± 0.5 vs. 1.1 ± 0.3, p < 0.01) than Non-progressors. At multivariable logistic regression analysis, Ra/Re ratio and arterial hypertension duration were independently associated with GFR decline (odds ratio [95% CI] 8.50 [1.56-46.28] and 1.14 [1.01-1.28]), respectively.
CONCLUSIONS: Increased Ra/Re ratio and arterial hypertension duration predict early GFR decline in hypertensive non-proteinuric type 2 diabetic patients. These findings could be explained by glomerular hypoperfusion and chronic ischemic injury related to pre-glomerular arteriolar narrowing. CLINICAL TRIAL REGISTRATION: DEMAND, NCT00157586, September 12, 2005.
© 2021. Springer-Verlag Italia S.r.l., part of Springer Nature.

Entities:  

Keywords:  Arterial hypertension; GFR decline; Glomerular hypoperfusion; Pre- and post-glomerular resistances; Type 2 diabetes

Mesh:

Year:  2021        PMID: 34648087     DOI: 10.1007/s00592-021-01804-9

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  33 in total

1.  Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?

Authors:  G Remuzzi; T Bertani
Journal:  Kidney Int       Date:  1990-09       Impact factor: 10.612

Review 2.  CKD in Aboriginal Australians.

Authors:  Wendy E Hoy; Priscilla Kincaid-Smith; Michael D Hughson; Agnes B Fogo; Rajalingam Sinniah; John Dowling; Terrence Samuel; Susan A Mott; Rebecca N Douglas-Denton; John F Bertram
Journal:  Am J Kidney Dis       Date:  2010-08-21       Impact factor: 8.860

Review 3.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

4.  Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.

Authors:  Annabelle M Warren; Søren T Knudsen; Mark E Cooper
Journal:  Expert Opin Ther Targets       Date:  2019-06-03       Impact factor: 6.902

Review 5.  Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".

Authors:  Giuseppe Pugliese; Giuseppe Penno; Andrea Natali; Federica Barutta; Salvatore Di Paolo; Gianpaolo Reboldi; Loreto Gesualdo; Luca De Nicola
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-10-02       Impact factor: 4.222

6.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

Review 7.  Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.

Authors:  Giuseppe Remuzzi; Ariela Benigni; Andrea Remuzzi
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

8.  Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1986-05       Impact factor: 1.713

9.  Glomerular hyperfiltration and renal disease progression in type 2 diabetes.

Authors:  Piero Ruggenenti; Esteban L Porrini; Flavio Gaspari; Nicola Motterlini; Antonio Cannata; Fabiola Carrara; Claudia Cella; Silvia Ferrari; Nadia Stucchi; Aneliya Parvanova; Ilian Iliev; Alessandro Roberto Dodesini; Roberto Trevisan; Antonio Bossi; Jelka Zaletel; Giuseppe Remuzzi
Journal:  Diabetes Care       Date:  2012-07-06       Impact factor: 19.112

10.  Diabetic kidney disease: a report from an ADA Consensus Conference.

Authors:  Katherine R Tuttle; George L Bakris; Rudolf W Bilous; Jane L Chiang; Ian H de Boer; Jordi Goldstein-Fuchs; Irl B Hirsch; Kamyar Kalantar-Zadeh; Andrew S Narva; Sankar D Navaneethan; Joshua J Neumiller; Uptal D Patel; Robert E Ratner; Adam T Whaley-Connell; Mark E Molitch
Journal:  Diabetes Care       Date:  2014-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.